Production (Stage)
Terns Pharmaceuticals, Inc.
TERN
$3.02
-$0.005-0.17%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 33.61M | 31.76M | 30.41M | 39.00M | 38.82M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 103.85M | 101.87M | 99.98M | 108.23M | 103.85M |
| Operating Income | -103.85M | -101.87M | -99.98M | -108.23M | -103.85M |
| Income Before Tax | -90.14M | -88.59M | -87.80M | -95.63M | -90.78M |
| Income Tax Expenses | 251.00K | 260.00K | 269.00K | 265.00K | 276.00K |
| Earnings from Continuing Operations | -90.39 | -88.85 | -88.07 | -95.90 | -91.06 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.39M | -88.85M | -88.07M | -95.90M | -91.06M |
| EBIT | -103.85M | -101.87M | -99.98M | -108.23M | -103.85M |
| EBITDA | -103.56M | -101.55M | -99.66M | -107.91M | -103.55M |
| EPS Basic | -1.09 | -1.13 | -1.18 | -1.31 | -1.26 |
| Normalized Basic EPS | -0.68 | -0.70 | -0.73 | -0.82 | -0.78 |
| EPS Diluted | -1.09 | -1.13 | -1.18 | -1.31 | -1.26 |
| Normalized Diluted EPS | -0.68 | -0.70 | -0.73 | -0.82 | -0.78 |
| Average Basic Shares Outstanding | 334.99M | 317.92M | 299.01M | 292.72M | 289.63M |
| Average Diluted Shares Outstanding | 334.99M | 317.92M | 299.01M | 292.72M | 289.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |